Cardiovascular disease is on the rise in the United States and the cost of CVD is continuing to rise to an estimated at $800 billion by 2030. Serum troponin level is one lab value that is used in early detection and evaluation of cardiovascular disease.
should be utilized. In utilization of troponins as an advanced practice clinician, the recommendation is to trend troponins per hospital policy, but also to become familiar in recognizing how elevated troponins can change the plan of care. Further research on the subject of trending troponins after myocardial infarction is still needed. (Heidenreich, Trogdon, Khavjou et al, 2011 ). An estimated $207 billion dollars are spent on cardiovascular care each year in the United States. The Center for Disease Control (CDC) closely monitors how various health disparities, including cardiovascular disease, impact people within the United States everyday. Some of the cardiovascular statistics collected include the cost of heart disease and the overall annual cost of health care services, medications, and lost productivity related to cardiovascular disease. Forty-nine percent of all Americans have at least three risk factors that contribute to an increased risk of cardiovascular disease. Risk factors include diabetes, obesity, poor diet, physical inactivity, or increased amounts of alcohol consumption. In the United States, one person will have a myocardial infarction (MI) every 42 seconds (CDC, 2017) . With the increasing number of Americans diagnosed with cardiovascular disease, it is important as clinicians, to find ways to accurately diagnose acute coronary syndrome (ACS) and the severity of cardiac damage in a timely fashion (Liu, Shehu, Herrold, & Cohen, 2015) . Troponin values can indicate the severity of the injury and research has shown an elevated troponin is highly predictive of increased mortality.
Identifying the extent of myocardial injury is critical function contributing to patient outcomes. Developing early treatment plans to best suit each individual patient is ideal. When clinicians order troponin levels for patients with a suspected MI and results of the troponin are elevated, this can provide diagnostic information, facilitate treatment 2 decisions, and promote early identification of a potential problem (Sara, Holmes, & Jaffe, 2015 providers. There appears to be many clinicians who choose to monitor serial levels until a downward trend is noted, while other clinicians do not.
Clinical practice guidelines are adopted with the intention to aid clinicians in prescribing evidence based and appropriate care. Contributors that set guidelines for troponin monitoring in ACS and acute myocardial infarction (AMI) include the European Society of Cardiology (ESC), the American College of Cardiology (ACC), and the American Heart Association (AHA) (Apple, Quist, Murakami, 2004 
Acute Coronary Syndrome
The American Heart Association (AHA) has focused on working towards saving and improving lives from heart disease and stroke for more than 90 years. Programs are available for patient and provider education, along with recommendations to reduce the risk of cardiovascular disease. The AHA acknowledges that utilizing personalized medicine and applying it to research involving cardiovascular disease (CVD) is ideal, although the funding is not currently available (Heidenreich, et. al, 2011) .
Many expenses currently spent on acute coronary syndrome (ACS) and the expected rise in medical costs that are directly related to cardiovascular disease are astronomical (Heidenreich et. al., 2011) . Research has been conducted to estimate the future costs of treatments for various components of cardiovascular disease, including: 5 hypertension, coronary artery disease, heart failure, stroke, and all other cardiac related diseases (Heidenreich, et. al, 2011) .
ACS is frequently what brings individuals to a hospital. The presentation of ACS symptoms will direct clinicians to further investigate individuals in order to rule out ACS.
According to the AHA, the criteria symptoms that define ACS include chest pain or discomfort that may involve pressure, tightness, or fullness in the chest and pain or a degree of discomfort in one or both arms, jaw, back, stomach, or neck. Shortness of breath, dizziness, lightheadedness, nausea, and sweating are additional symptoms that indicate ACS. A diagnostic workup includes an ECG, as well as obtaining blood tests or markers to assess for myocardial injury or an ACS (AHA, 2015) .
Troponin markers are fairly new indicators, introduced in the 1990's, and have been initiated as the primary source of cardiovascular morbidity risk identification. Prior to the troponin markers, CPK markers were used to identify cardiac muscle breakdown, but many hospitals adopted the use a troponin level over a CPK due to its ability to provide a more rapid biomarker in the diagnose of an AMI. The troponin level directly correlates to myocardial muscle damage rather than skeletal muscle damage (Edwards, et al., 2013) . Troponin levels are primarily ordered to determine an AMI and to assess the amount of myocardial damage, as shown by the sensitivity of the troponin assay (Wu, Bolger, & Hollander, 2013 ).
An extensive work up, including telemetry monitoring, ECG and serial troponin levels, can identify ACS, as well as detect any myocardial damage that may have occurred. Bjorklund et al. (2003) Patients with positive ST elevation were older, had an increased heart rate, a higher probability of anterior infarct, and a longer time from symptom onset to intervention.
The researchers were able to determine that patients who had a positive troponin and STElevations had a higher mortality rate within one year (Bjorklund, et al., 2003) .
Troponin Benefits
Troponin testing was introduced in the early 1990's. Questions about the relationship between the physiological findings of elevated troponin as a marker of myocardial necrosis and the clinical significance of the finding have developed over time.
The early testing demonstrated that an elevated troponin level identified patients who had an increased risk for adverse outcomes: whether their presenting clinical diagnosis was related to unstable angina, myocardial infarction (MI), or a non-coronary etiology.
Traditionally clinicians used multiple modalities of diagnostic judgment including the physical exam, the patient history, ECG imaging, and various blood tests to determine if an admission was warranted. Research attempted to evaluate various blood tests that 7 were useful in diagnosing a AMI. Later, strategic goals of research included cost effectiveness and the predictive values of diagnostic studies (Luscher, Ravkilde, & Thygesen, 1998) . Rahimi, Marzano, & Richard (2003) conducted a study at a medical center in Georgia to evaluate if the serum lactate, c-reactive protein creatine phosphokinasemuscle/brain (CPK-MB) and troponin levels are useful in diagnosing an AMI. Inclusion criteria included all patients that presented to the hospital with symptoms associated with an AMI regardless of age, race, gender, or other previously identified comorbidities.
Sixty-two patients met the eligibility to participate. Exclusion criteria were all patients with heart failure, cardiogenic shock, active seizure activity, alcohol intoxication, acute and chronic renal failure, smoke inhalation, received cardiopulmonary resuscitation, chest pain that had been persistent for greater than 24 hours, and acute ST-segment elevation on ECG. Blood draws were initiated on admission, 2 hours after admission, and again at the 4-hour interval. Of the 62 patients selected for the study, 18 had a documented AMI and required further interventions such as thrombolytics, angioplasty, and stenting.
The results of the study indicated that the individuals that underwent serial blood testing, including lactate levels, creatine-kinase myoglobin (CK-MB), and troponin correlated to similar results. The lactate had a sensitivity of 75%, and the specificity of 95.5%. The positive predictive value of the lactate was 91.3%. Conclusions drawn indicated that the lactate level could be used in the emergency room as a rapid assessment tool to diagnose an AMI in an emergency, although it wasn't meant to replace the other cardiac enzymes such as CK-MB and troponin monitoring. One of the disadvantages of 8 this study was the small sample size, utilizing data from 18 participants (Rahimi, Marzano, & Richard, 2003) .
The progression of diagnosing an AMI has dramatically changed from thirty years ago. Previously, the clinician's steps to diagnose a patient with having an AMI looked at the following criteria: the patient's clinical history, the ECG findings, and temporary changes in the CK-MB. Currently, clinicians still utilize ECG findings, patient's clinical history, and a troponin level to diagnose coronary injury (Luscher, Ravkilde, & Thygesen, 1998 ).
Lindahl, Venge & Wallentin (1995) conducted a seminal study to evaluate whether using a CK-MB, troponin, or myoglobin aided with the early diagnosis of an AMI. The study was conducted in two teaching hospitals and four county hospitals in
Sweden. This study included 142 patients admitted to the hospital with persistent chest pain for less than 12 hours and a non-diagnostic ECG. Patients who came in with over twelve hours of chest pain were excluded from the study. The participants underwent blood draws every 30 minutes during the first three hours. Blood draws included monitoring the combination of the CK-MB, myoglobin, and troponin. At the completion of the study, the researchers indicated that both the troponin and myoglobin samples were identical in sensitivity at the 4-hour mark. However, the first blood sample wasn't sensitive or specific enough to exclude or make a confirmation of an AMI. Troponin and myoglobin was found to be slightly inferior in sensitivity in comparison to the CK-MB.
Results indicated that no single marker individually provided the high sensitivity or specificity that would indicate AMI (Lindahl, Venge & Wallentin, 1995) .
Serial Troponin Levels
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Troponin levels have been identified as the preferred serologic biomarker to identify ACS (Wu, Bolger, & Hollander, 2013 (Wu, Bolger, & Hollander, 2013) .
A retrospective case control study was conducted in 2013 to determine which troponin sample drawn out of multiple samples taken would be the most important one in diagnosing an AMI (Edwards, et al., 2013) . The researchers stated that patients were formerly evaluated solely based on criteria that includes: past medical history, physical exam, ECG analysis, CK and CK-MB levels. One hundred subjects were selected for the study by the way of convenience sampling for a chart review. The subjects in both groups included both men and women who were between 40 and 79 years of age and were diagnosed with an AMI between January 1, 2010 and December 31, 2010. The control group was created by performing a chart review containing subjects that only received one blood draw. Subjects that had 3 sets of blood draws on chart review composed the experimental group. The subjects selected had angina pectoris on admission to the emergency room and the frequency of sampling was scheduled to occur for multiple other draws at hours 3, 6, 8, and 12 hours to diagnose AMI. The CTnI lower level of detection that was used was 0.4ng/mL. The high reference limit of the CTnI was 1.5mg/mL. The statistical analysis was conducted using a α = 0.05 significance level. The AMI cases were identified retrospectively by utilizing the ICD-9 codes that indicated 10 chest pain or AMI. The results indicated that 78% of cases (n = 50) were diagnosed with AMI at the initial troponin draw. Fourteen percent were diagnosed at the hour six. The authors indicated that the initial troponin is clearly the most important in determining the presence or absence of an AMI. Age was mentioned as a strong contributor to an increased risk of an AMI. The results of this study indicated that the initial troponin level was the most important in diagnosing an AMI. Limitation of the study included the small sample size, and not obtaining other blood work that is frequently included as cardiac to diagnose an AMI such as the CK-MB (Edwards, et al., 2013) .
High Sensitivity versus Conventional Troponin
Troponin levels have advanced to a new high sensitivity troponin assay (hsTrop).
Research is beginning to evaluate if this high sensitivity troponin value is more CTnI blood draw had a greater increase for coronary angiography, 77% compared to 55%
of individuals who were evaluated by the hsTrop. Some of the concluding data indicated that the hsTrop provided a more complex evaluation of chest pain, with fewer invasive tests and more tests such as stress tests, being done. The hsTrop group demonstrated a higher incidence of pharmacological treatments and a longer hospitalization, although at the end of six months, the clinical outcomes of both groups of patients were similar (Sanchis, et al., 2014) . Research has not shown hsTrop to be more beneficial than CTnI from a cost standpoint or for diagnosing ACS. Troponin values, especially the initial troponin, are continuously being reviewed, monitored, and researched (Wu, Bolger, Hollander, 2013) . Liu, Shehu, Herrold & Cohen (2015) looked at CTnI levels within a 24-hour period in critically ill patients to determine if the serum level of CTnI in non-ACS patients admitted to the intensive care unit (ICU) or the critical care unit (CCU) have any prognostic value and whether the CTnI results will improve the quality of care and allocation of resources. The study was an observational study conducted on all patients that were admitted to the ICU or CCU at a teaching hospital in the United States.
Inclusion criteria for the observational study were patients that presented with at least one elevated CTnI within a 24-hour admission period. The patients were divided into two groups based on the highest troponin level. If the peak CTnI was more than 0.049ng/mL, they were placed in a CTnI positive group. If the peak level was 0.049ng/mL or less, participants were placed into the CTnI negative group. The results of the two groups were compared. Exclusion criteria were patients with ACS in their medical history, physical examination, clinical features, cardiac biomarkers, or electrocardiographic findings.
During the 115-day period, 90 patients qualified for the study, forty patients were placed in the CTnI positive group, and 50 patients were placed in the CTnI negative group.
Regardless of the baseline characteristics of individuals who participated in the study, hospital mortality was significantly higher in the CTnI-positive group than in the CTnInegative group. The length of stay between these two groups did not differ significantly.
One significant difference identified was that more patients had a history of COPD in the CTnI positive group. Sepsis, heart failure, pulmonary embolism, renal failure, and COPD can all cause an elevation of the CTnI related to cardiac-demand ischemia. An elevated CTnI within 24-hours of admission to ICU or CCU was identified as an increased risk for mortality and higher incidence of intubation in non-ACS critically ill patients (Liu et al., 2015 (Lim, et al., 2006 ). An AMI not caused by an occlusion from a thrombus or calcification may not respond favorably to the aforementioned therapies and the impact of these therapies on patient outcomes is unknown (Lim, et al., 2006) .
Themes found in the literature indicate that a serum troponin level is preferred over the CK-MB because troponin exclusively indicates myocardial damage or ischemia that will decrease the functionality of the myocardium, while the CK-MB is not exclusive to the myocardium (Liu, Shehu, Herrold, Cohen, 2015 (Wu, Bolger, Hollander, 2013) .
Provider Preference of Troponin Monitoring
Providers have traditionally utilized the guidelines set forth by the ESC, ACC and AHA to evaluate and trend cardiac enzyme values. A key component in a patient care includes coming up with a differential diagnosis. In developing a differential diagnosis, it is still relevant to evaluate the patient for a previous cardiac history or medical history that would predispose a patient and place them at a higher risk of ACS. ECG's and blood levels all contribute to aiding the diagnosis of ACS. The ESC, ACC, and AHA have compiled current research that examines the validity and sensitivity of cardiac biomarkers, and how to best utilize them to diagnose a patient with an AMI, including timed interventions and how they can directly correlate to decreasing the morbidity and mortality with ACS. The guidelines provided by the ESC, ACC, and AHA include some of the latest research on diagnosing an AMI. Hospitals and providers can choose to adapt to the newest research, or develop policies based on the information set forth by the ESC, ACC and AHA, although this may not be mandatory. Currently some hospitals and providers do not use the serum troponin as the standard diagnostic tool for diagnosing 15 AMI. For example, a hospital that conducted troponin research in Georgia utilized the CK-MB assay for diagnosing and ruling out an AMI (Edwards, et al., 2013) .
Clinicians spend time in finding ways to accurately diagnose ACS. After drawing troponin levels and a diagnosis of ACS is determined, many patients will undergo a cardiac intervention. After intervention, many times cardiac troponins are not routinely ordered at timed intervals for monitoring. A gap in the research includes troponin monitoring after myocardial infarction, as well as trending troponins after coronary intervention to evaluate the presence and extent of disease. Much of the research focuses on the diagnosis and prompt treatment of ACS because research indicates that a positive troponin increases the morbidity and mortality risk. Further evidence is warranted in the duration and frequency of troponin monitoring following AMI and subsequent cardiac interventions (Liu et al., 2015) .
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Theoretical Framework
The theoretical framework that guided this qualitative study of clinician preference regarding troponin monitoring following AMI is the ACE Star Model of the Cycle of Knowledge Transformation (Star Model) (Stevens, 2002) . The Star Model utilizes evidence-based practice (EBP) to create a framework that utilizes old and new concepts to improve care as a whole (Stevens, 2002) . The Star Model is "configured as a simple 5-point star that illustrates five major stages of knowledge transformation" (Stevens, 2002) .
The first point of the star is identified as Discovery (Stevens, 2002) . During the discovery stage, new knowledge and original research is reviewed to form a design that could be descriptive, correlational, or qualitative (Stevens, 2002) . Research reviewed in the current literature reveals the importance of troponin monitoring in cardiac patients.
The qualitative questions developed attempt to discover if previous research guided clinician decisions about the timing of troponin draws, as well as interpretation of the troponin results.
The second point of the star is Evidence Summary (Stevens, 2002) . Evidence
Summary is taking single meaningful statements to combine findings from various studies to identify bias (Stevens, 2002) . Evidence summary works on combining information that includes clinical care, economic decisions, future research design and policy formation (Stevens, 2002) . Evidence summary guides the questionnaire in finding out if trending troponin values are substantial in developing a plan for patient care.
The third point of the star is Translation (Stevens, 2002) . Translation takes relevant and useful information and summarizes the information that can be translated 17 into clinical practice guidelines that defines the standards of care, clinical pathways and algorithms (Stevens, 2002) . The Translation point of the star indicates current guidelines about troponin monitoring and how troponin values can be integrated into practice by utilizing current knowledge.
The fourth point of the star is Implementation (Stevens, 2002) . Implementation looks at current practice that utilizes evidence based research to develop steps to implement a change within an institution to improve on patient care (Stevens, 2002) .
The fifth point of the star is Evaluation (Stevens, 2002) . Evaluation looks at the impact of EBP on patient's health, outcomes, efficacy, efficiency, economic analysis and the overall impact of health. The overall goal is to utilize the ACE Star Model to determine the trends of troponin monitoring and translate the information into recommendations. For the purposes of this project, this project only utilized the first three points of the Star Model.
Method Purpose
The purpose of this qualitative study was to evaluate the clinician's preference of troponin monitoring after a MI.
Design
A descriptive four open-ended qualitative questionnaire was used to evaluate preferences of clinicians regarding troponin monitoring (Appendix A).
Site
The study took place at suburban hospital located in Providence Rhode Island.
This hospital is a teaching hospital that currently holds 247 beds. The Coronary Care
Unit has nine beds. Approximately 15,000 cardiac patients are cared for at The Miriam
Hospital in a year. The survey was conducted in the physician's conference room.
Sample
The sample included cardiac clinicians currently working in the Coronary Care
Unit. Eligible clinicians included cardiologists, cardiac fellows, cardiac nurse practitioners, and cardiac physician assistants. Clinicians who attend the cardiology meeting and are directly involved in cardiac care were included in the study. Exclusion criteria for the study were non-cardiac clinicians. Twenty-three clinicians were eligible to participate. The goal was to obtain a response from at least ten clinicians who attended the monthly meeting.
Procedures
A questionnaire (Appendix A) was developed after completing a literature review and finding gaps in the research that didn't include troponin monitoring or trending after Provide rationale. All participants stated ordering a high sensitivity troponin. The rationale included using a high sensitivity troponin because the hospital has changed over from the standard troponin to now a high sensitivity and this is the only one currently available at the hospital. (Stevens, 2002) . A recommendation for practice provided by one of the clinicians who completed the questionnaire included continuous troponin monitoring until the patient is discharged.
The rationale would be to determine the extent of cardiac damage as well as if the patient is readmitted with chest pain within the span of a day or a few days, the results of the last troponin could indicate a baseline troponin level after coronary intervention. If a patient is readmitted with a higher level then the last drawn value on discharge, this could indicate further disease or another valid comorbidity.
Literature reviewed included research that focused on utilizing troponins for the purpose of early diagnosis of ACS. Research also looked at the extent of morbidity and mortality rates of patients that had a positive or greater than normal level of troponin and the differences between a CTnI and a hsTrop. A gap in the research was the lack of data regarding trending of troponins after intervention. This project attempted to find out more information about clinician preference of troponin monitoring after myocardial 27 infarction. In utilization of troponins as an advanced practice clinician, a recommendation would be to trend troponins per hospital policy, but also to become familiar in recognizing how elevated troponins can change the plan of care. Further research is still needed on troponin monitoring after myocardial infarction.
